äžŽåºæŽæ°ð
â $Larimar Therapeutics (LRMR.US)$ ð¢
⣠FDAåæ¶éšåäžŽåºææ
â£ è¯ºå§æåæ¬§åžå»è¯(CTI-1601) #FA
⣠èçœæ¿ä»£çæ³
⣠24幎第åå£åºŠOLPçäžŽæ¶æ°æ® ð
â $Larimar Therapeutics (LRMR.US)$ ð¢
⣠FDAåæ¶éšåäžŽåºææ
â£ è¯ºå§æåæ¬§åžå»è¯(CTI-1601) #FA
⣠èçœæ¿ä»£çæ³
⣠24幎第åå£åºŠOLPçäžŽæ¶æ°æ® ð
䞎åºç»æ ð¢
â $Citius Pharmaceuticals (CTXR.US)$ ð¢
⣠积æç第äžé¶æ®µäžåžç»æ
⣠57.1% çæ£è æ²»çæ»äœæå
â $Citius Pharmaceuticals (CTXR.US)$ ð¢
⣠积æç第äžé¶æ®µäžåžç»æ
⣠Mino-Lok® #CLABSI #CRBSI
⣠æççŽ é宿º¶æ¶²â£ 57.1% çæ£è æ²»çæ»äœæå
çç®¡æŽæ°ð¯
â $奥æŽå ¹çŸå»ç (HALO.US)$$æœèŽµå® (BMY.US)$
⣠FDAéæ°åé PDUFAæ°æ®è³24幎12æ29æ¥
⣠äºåéœèªäœTç»èæ²»ç
â $奥æŽå ¹çŸå»ç (HALO.US)$$æœèŽµå® (BMY.US)$
⣠FDAéæ°åé PDUFAæ°æ®è³24幎12æ29æ¥
⣠äºåéœèªäœTç»èæ²»ç
w/ENHANZE
å
莣声æïŒç€Ÿåºç±Moomoo Technologies Inc.æäŸïŒä»
çšäºæè²ç®çãæŽå€ä¿¡æ¯
è¯è®º
å衚è¯è®º
4
